Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

PURPOSE: This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. PATIENTS AND METHODS: A total of 1,538 patients with resected pT2 (high grade) or ≥ pT3, including N1,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Motzer, Robert J., Haas, Naomi B., Donskov, Frede, Gross-Goupil, Marine, Varlamov, Sergei, Kopyltsov, Evgeny, Lee, Jae Lyun, Melichar, Bohuslav, Rini, Brian I., Choueiri, Toni K., Zemanova, Milada, Wood, Lori A., Reaume, M. Neil, Stenzl, Arnulf, Chowdhury, Simon, Lim, Ho Yeong, McDermott, Ray, Michael, Agnieszka, Bao, Weichao, Carrasco-Alfonso, Marlene J., Aimone, Paola, Voi, Maurizio, Doehn, Christian, Russo, Paul, Sternberg, Cora N.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2017
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018511/
https://ncbi.nlm.nih.gov/pubmed/28902533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.5324
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki